Single LSD dose provides lasting anxiety relief: Research

The U.S. Food and Drug Administration (FDA) is making a breakthrough in prescribing LSD to treat generalized anxiety disorder after initial studies show that a single dose of the drug provides lasting relief. It has been given the status as a treatment method.

The LSD therapy developed by Mind Medicine (MindMed) has to go through the standard FDA approval process and will soon enter Phase 3 clinical trials.

The study, which prompted the FDA’s move forward, found that the drug was “generally well-tolerated, with most adverse events assessed to be mild to moderate, transient, and occurring on the day of administration,” and that It was found that this is consistent with the acute effect of According to the release About the survey results.

The most common side effects on the first “day of administration,” or when a patient first receives the drug, include hallucinations, euphoria, unusual thinking, headaches, dizziness, and nausea.

The company plans to meet with the FDA in the coming months to obtain an update and begin an expanded clinical program in the second half of this year.

MindMed is a pharmaceutical company focused on developing hallucinogens as medicines, and has spent years researching the potential medical uses of LSD, an illegal drug that has not previously been approved for medical use. I’m here. The specific LSD formula obtained in this study is called MM120.

The study’s investigator, Dr. David Feifel, a California-based psychiatric researcher, called the findings “truly remarkable.”

“I have been conducting clinical research in psychiatry for over 20 years and have seen many drug studies in development for the treatment of anxiety disorders,” he said in a statement provided by the company. Ta. “These results suggest the potential of MM120 in the treatment of anxiety disorders, and we look forward to seeing the results of future Phase 3 trials as we strive to reduce anxiety in patients every day. I’m looking forward to it.”